부산대학교 도서관

Newer cytogenetic scoring systems for myelodysplastic syndromes (MDSs), like cytogenetic stratification of the revised international prognostic scoring system (IPSS-R) or monosomal karyotype, may also improve outcome prediction after hematopoietic SCT (HCT). We compared the prognostic value of specific cytogenetic abnormalities, IPSS-R karyotype and monosomal karyotype for HCT outcome in 98 patients with MDS and AML post MDS. Higher-risk IPSS-R karyotype, 3q21q26 and transformation to AML before HCT were associated with increased cumulative incidence of relapse (CIR), whereas OS was adversely influenced by del 5q/-5, abnormalities of chromosomes 11 and 17 and cytogenetic IPSS-R very poor category. Karyotype with [less than or equal to] 2 abnormalities and no abnormalities of chromosomes 3, 5, 7, 11 and 17 was an independent prognostic factor of lower CIR (hazard ratio (HR) = 0.2, P = 0.01) and longer OS (HR = 0.5, P = 0.03). In conclusion, some specific cytogenetic abnormalities and high cytogenetic complexity, as reflected by IPSS-R very poor karyotype, rather than monosomal karyotype, were associated with higher CIR and shorter OS after HCT. Conversely, results were encouraging in patients lacking those abnormalities, who may be very good candidates for HCT. Bone Marrow Transplantation (2014) 49, 1022-1028; doi: 10.1038/bmt.2014.87; published online 5 May 2014
INTRODUCTION Myelodysplastic syndromes (MDSs) are clonal myeloid disorders characterized by ineffective hematopoiesis and a high incidence of transformation to AML. (1,2) The International Prognostic Scoring System (IPSS) and, more recently, [...]